Cadila Pharma to hold life sciences-focused innovation conclave IAMICON 2014


Ahmedabad, 12 November 2014

Cadila Pharmaceuticals Limited – one of India’s largest privately-held pharmaceuticals companies – will host IAMICON 2014 (Indravadan Ambalal Modi Innovation Conclave), India’s biggest scientific conclave to celebrate Innovation and Excellence in the Pharmaceuticals and Life Sciences sector. Covering 50 cities across India, IAMICON 2014 will focus on advances in the treatment of Tuberculosis and Cardiovascular diseases. Cadila Pharmaceuticals is committed to Government of India’s ‘TB-Mission 2020’, which seeks to eliminate Tuberculosis from the country.

Conceived to celebrate Innovation and Excellence in the Pharmaceuticals and Life Sciences sector, IAMICON will bring together the world’s brightest minds in Medical Science to discuss and disseminate the latest updates in Science and Medicine.

In the run-up to the event, Dr. Rajiv Modi, Chairman and Managing Director, Cadila Pharmaceuticals Ltd. said, “India’s pharmaceuticals sector has creditable contribution in providing affordable medicines to patients in India and across the globe. There have been bright sparks of innovation in our country, which have not received due attention. By showcasing such efforts every year and promoting the spirit of Indian innovation, IAMICON seeks to pay eternal tribute to our Founder-Chairman Shri Indravadan Ambalal Modi, the legendary Medicine Man of India. In his perennial quest for making medicines affordable to the last man in the society, he accorded highest importance to research and innovation. He put in path-breaking efforts to have process patents recognized and his initiatives culminated in the amended Indian Patents Act, 1970, which recognized process patents and helped pioneer India’s generics industry.”

To be launched on November 14 at New Delhi, IAMICON 2014 will be held across the country on November 14-15-16 and November 21-22-23 in 50 cities across India. More than 300 national and international speakers and 20,000-plus doctors will participate in India’s biggest medical knowledge conclave.

Amongst the leading R&D companies in India, Cadila Pharmaceuticals has focused on providing innovative solutions for human healthcare. The Company has a noteworthy track record of launching many first-in-the-world innovative products such as Polycap (5-in-1 polypill for prevention and treatment of Cardiovascular Diseases) and Risorine (innovative solution to treat Tuberculosis). In 2013, the Company introduced Mycidac-C – the world’s first active immunotherapy for lung cancer at almost one-tenth the cost of those made by multinational companies.

“Besides the latest updates in medical science, IAMICON 2014 will simultaneously spotlight the work of some eminent practitioners who will focus on advancements in treating TB and Cardiovascular Diseases. Through the ‘Indravadan Ambalal Modi Academic Excellence Awards’, IAMICON will also felicitate and encourage bright doctors with excellent academic performance in their post-graduate medical studies,” revealed Dr. Modi.

Many reputed speakers from the Pharmaceuticals and Healthcare sectors are slated to participate and share their valuable insights during IAMICON 2014. Professor Brendan Madden, Director, Endobronchial Intervention and Pulmonary Hypertension Services (UK); Mr Kenneth J Giacin, Chairman, StemCyte Inc. (USA); Dr Wise Young, Chief Science & Medical Advisor, StemCyte Inc. (USA); Professor Sir Anthony Coates, Founder, Helperby Therapeutics Ltd (UK); and Dr. Nikhil Parchure, Consultant Cardiologist (UK) will be the keynote speakers, amongst several other speakers of national eminence, at the Conclave.